Forma Life Sciences, which inherited BioDuro’s California production operations earlier this year, has officially launched as a CDMO with a focus on oral solid-dosage drugs.
The new contract manufacturing and development organization was established following BioSelective Capital Investments' purchase of a pair of BioDuro production and development plants in Irvine, California, in January. The deal gave Forma more than 100,000-square-feet of manufacturing space, including 27 production suites with the ability to churn out more than 2 billion tablets and capsules a year.
Across both Irvine sites, Forma says it's equipped for oral solid dose formulation development, clinical manufacturing through phases 1-3, process scale-up and tech transfer, and commercial drug product production.
The company is led by Cyrus Mirsaidi, who holds the title of executive chairman and CEO. Mirsaidi was CEO of BioDuro from 2015 to 2021. Armand Amin, also a former leader at BioDuro, was named Forma’s president and head of business operations.
“Our industry is seeing renewed focus on domestic pharmaceutical manufacturing and supply chain resilience,” Amin said in a statement. “Forma provides a durable, U.S.-based development and manufacturing platform that pharmaceutical and biotechnology partners can rely on from clinical development through commercial supply.”
Forma is among a clutch of new CDMOs that have launched in recent months.
In Early December, Buckland Group-backed Quvara Medical debuted after it bought a former Becton Dickinson manufacturing site in the U.K. for an undisclosed price.
Other notable CDMO launches in 2025 included Rezon Bio, Codis, Meribel and Artis BioSolutions.
For its part, the U.S.-based BioDuro recently shed its Irvine facilities as it focuses on its established manufacturing muscle in Asia and China specifically. Earlier this week, the company announced a production joint venture with Taiwanese API maker Cenra API Solutions.